---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000017"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:01:16.380675+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan

## Summary
- Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.
- Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.
- Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.
- Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.
- Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma.

## SEC filing metadata
- accession: 0001396814-25-000017
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/pcrx-20250116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000017
- JSON: https://secwatch.observer/filing/0001396814-25-000017.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000017.txt

## Key facts
- Executive change
  Brendan Teehan was appointed as Chief Commercial Officer at Pacira BioSciences, Inc..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm
- Executive change
  Daryl Gaugler was named as Executive Vice President, Commercial Operations at Pacira BioSciences, Inc..
  - Action: named
  - Role: Executive Vice President, Commercial Operations
  source text: On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.